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to view.Safety and Effectiveness of Everolimus-Eluting Stents in Chronic Total Coronary
Occlusion Revascularization: Results From the EXPERT CTO Multicenter Trial
(Evaluation of the XIENCE Coronary Stent, Performance, and Technique in
Chronic Total Occlusions)761David E. Kandzari, Annapoorna S. Kini, Dimitri Karmpaliotis, Jeffrey W. Moses,
Pradyumna E. Tummala, J. Aaron Grantham, Charles Orr, William Lombardi,
William J. Nicholson, Nicholas J. Lembo, Jeffrey J. Popma, Jin Wang,
Cristina Larracas, David R. RutledgeAmong 250 patients undergoing attempted chronic total occlusion (CTO) percutaneous coronary
intervention (PCI) with everolimus-eluting stents (EES), procedural outcomes and the 1-year
primary endpoint of death, myocardial infarction, and target lesion revascularization (major adverse
cardiac events [MACE]) were examined. Compared with a pre-speciﬁed performance goal derived
from prior CTO trials (1-year MACE: 24.4%), treatment with EES was associated with signiﬁcantly
lower adverse events by both intent-to-treat (18.5%, 1-sided upper conﬁdence interval [CI]:
23.4%, p ¼ 0.025) and protocol deﬁnitions (8.2%, 1-sided upper CI: 12.3%, p < 0.0001). These
results indicate favorable procedural success and late-term clinical outcomes to support CTO PCI in
a patient population with high lesion complexity.
SEE ADDITIONAL CONTENT ONLINEClinical, Angiographic, Functional, and Imaging Outcomes 12 Months After Implantation
of Drug-Eluting Bioresorbable Vascular Scaffolds in Acute Coronary Syndromes770Tommaso Gori, Eberhard Schulz, Ulrich Hink, Madeleine Kress, Nadja Weiers,
Melissa Weissner, Alexander Jabs, Philip Wenzel, Davide Capodanno, Thomas MünzelThis study reports on the 12-month clinical, angiographic, imaging, and functional outcomes after
implantation of bioresorbable scaffolds for the treatment of acute coronary syndromes.
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MAY 2015 VOLUME 8, NUMBER 6Biochemical Validation of Patient-Reported Symptom Onset Time in Patients With
ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous
Coronary Intervention778Karim D. Mahmoud, Hans L. Hillege, Allan S. Jaffe, Ryan J. Lennon, David R. Holmes, Jr.Symptom onset time is an important metric in patients with ST-segment elevation myocardial
infarction. It may be used to select a reperfusion strategy and calculate ischemic time, which has
quality of care and prognostic importance. Despite these features, symptom onset time has never
been validated. The authors performed a biochemical validation of patient-reported symptom
onset time by backward modeling of serial increasing cardiac troponin T measurements. This study
found that biochemical onset time was typically earlier than the reported symptom onset time
(median difference: 4.2 h). This phenomenon was exacerbated in speciﬁc subgroups. Recalculation
of ischemic time with biochemical onset time enhanced its prognostic value.
SEE ADDITIONAL CONTENT ONLINEn EDITORIAL COMMENT
A New Time Clock for ST-Segment Elevation Myocardial Infarction 788
Bruce R. Brodie
Sex-Related Outcomes in Elderly Patients Presenting With Non–ST-Segment Elevation
Acute Coronary Syndrome: Insights From the Italian Elderly ACS Study791Marco De Carlo, Nuccia Morici, Stefano Savonitto, Vincenzo Grassia, Paolo Sbarzaglia,
Paola Tamburrini, Claudio Cavallini, Marcello Galvani, Paolo Ortolani, Stefano De Servi,
A. Sonia PetronioThis study investigated sex-related differences in 645 elderly patients (mean age, 82 years) with
non–ST-segment elevation acute coronary syndromes (NSTEACS) enrolled in the Italian Elderly
ACS study, which consisted of a randomized trial and a parallel registry. Women had a risk proﬁle
similar to men, but underwent signiﬁcantly fewer revascularizations during the index admission.
In-hospital adverse event rates were similar in both sexes. Women showed a signiﬁcantly lower
1-year rate of the composite primary endpoint. The 3-fold lower in-hospital and 1-year mortality
associated with coronary revascularization in women supports an early revascularization strategy
in elderly women with NSTEACS.n EDITORIAL COMMENT
Improving Outcomes in Older Women? 797
John A. Dodson, Judith S. HochmanCONTINUED ON PAGE A-26
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MAY 2015 VOLUME 8, NUMBER 6Effect of Daily Glucose Fluctuation on Coronary Plaque Vulnerability in Patients
Pre-Treated With Lipid-Lowering Therapy: A Prospective Observational Study800Masaru Kuroda, Toshiro Shinke, Kazuhiko Sakaguchi, Hiromasa Otake,
Tomofumi Takaya, Yushi Hirota, Daisuke Sugiyama, Masayuki Nakagawa,
Hirotoshi Hariki, Takumi Inoue, Tsuyoshi Osue, Yu Taniguchi, Masamichi Iwasaki,
Ryo Nishio, Hiroto Kinutani, Akihide Konishi, Noritoshi Hiranuma, Hachidai Takahashi,
Daisuke Terashita, Ken-ichi HirataThere is growing evidence that glucose ﬂuctuation, as a residual risk apart from dyslipidemia, is an
important contributing factor to the development of coronary artery disease (CAD). By using
virtual histology intravascular ultrasound and continuous glucose monitoring, the authors found
that the mean amplitude of glycemic excursion, representing daily glucose ﬂuctuation, was
strongly associated with both the larger percentage of necrotic core within the plaque and the
higher presence of thin-cap ﬁbroatheroma. This suggests that there may be a rationale for the
early detection and control of glucose ﬂuctuation in the era of universal statin use for CAD patients.n EDITORIAL COMMENT
Blood Glucose Variability: A New Metric for Interventional Cardiology? 812
Michael E. Farkouh
In-Stent Yellow Plaque at 1 Year After Implantation Is Associated With
Future Event of Very Late Stent Failure: The DESNOTE Study (Detect the Event of
Very late Stent Failure From the Drug-Eluting Stent Not Well Covered by
Neointima Determined by Angioscopy)814Yasunori Ueda, Koshi Matsuo, Yuji Nishimoto, Ryuta Sugihara, Akio Hirata,
Takayoshi Nemoto, Masato Okada, Ayaka Murakami, Kazunori Kashiwase,
Kazuhisa KodamaThis study sought to examine whether the presence of in-stent yellow plaque at 1 year after the
implantation of a drug-eluting stent would be associated with the subsequent (very late) stent
failure, consecutive 360 patients who received successful angioscopic examination at 1 year after
implantation of drug-eluting stent were included. The follow-up interval was 4.3  2.4 years. The
incidence of the event was signiﬁcantly higher in the patients with yellow plaque than in those
without (8.1% vs. 1.6%; log rank p ¼ 0.02). The underlying mechanism of very late stent fracture
appeared to be the progression of atherosclerosis as demonstrated by yellow plaque.n EDITORIAL COMMENT
Neoatherosclerosis: Detection and Clinical Consequences 822
Cindy L. Grines, Theodore L. SchreiberCONTINUED ON PAGE A-27
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MAY 2015 VOLUME 8, NUMBER 6Prospective Assessment of the Diagnostic Accuracy of Instantaneous Wave-Free Ratio
to Assess Coronary Stenosis Relevance: Results of ADVISE II International, Multicenter
Study (ADenosine Vasodilator Independent Stenosis Evaluation II)824Javier Escaned, Mauro Echavarría-Pinto, Hector M. Garcia-Garcia, Tim P. van de Hoef,
Ton de Vries, Prashant Kaul, Ganesh Raveendran, John D. Altman, Howard I. Kurz,
Johannes Brechtken, Mark Tulli, Clemens Von Birgelen, Joel E. Schneider,
Ahmed A. Khashaba, Allen Jeremias, Jim Baucum, Raul Moreno, Martijn Meuwissen,
Gregory Mishkel, Robert-Jan van Geuns, Howard Levite, Ramon Lopez-Palop,
Marc Mayhew, Patrick W. Serruys, Habib Samady, Jan J. Piek, Amir Lerman,
on behalf of the ADVISE II Study GroupADVISE II (ADenosine Vasodilator Independent Stenosis Evaluation II) was a large, multicenter, core
laboratory–based study designed to prospectively investigate the diagnostic accuracy of
instantaneous wave-free ratio (iFR) against fractional ﬂow reserve (FFR). Outside of pre-speciﬁed
treatment (#0.85) and deferral ($0.94) values, iFR correctly classiﬁed 91.6% of the stenoses.
When combined with FFR use within these cut-offs, the pre-speciﬁed hybrid iFR-FFR approach
correctly classiﬁed 94.2% of total stenoses and obviated vasodilators from 65.1% patients and
69.1% stenoses. Therefore, ADVISE II supports the diagnostic value of iFR in establishing the
functional signiﬁcance of coronary stenoses and highlights its complementariness with FFR when
used in a hybrid iFR-FFR approach.
SEE ADDITIONAL CONTENT ONLINEn LETTER TO THE EDITOR
Diagnostic Accuracy of Baseline Distal-to-Aortic Pressure Ratio to Assess
Coronary Stenosis Severity: A Post-Hoc Analysis of the ADVISE II Study834Mauro Echavarría-Pinto, Tim P. van de Hoef, Hector M. Garcia-Garcia, Ton de Vries,
Patrick W. Serruys, Habib Samady, Jan J. Piek, Amir Lerman, Javier Escaned,
on behalf of the ADVISE II Study GroupCONTINUED ON PAGE A-28
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MAY 2015 VOLUME 8, NUMBER 6STRUCTURAL Optimal Implantation Depth and Adherence to Guidelines on Permanent Pacing
to Improve the Results of Transcatheter Aortic Valve Replacement With the
Medtronic CoreValve System: The CoreValve Prospective, International,
Post-Market ADVANCE-II Study837Anna S. Petronio, Jan-Malte Sinning, Nicolas Van Mieghem, Giulio Zucchelli,
Georg Nickenig, Rafﬁ Bekeredjian, Johan Bosmans, Francesco Bedogni, Marian Branny,
Karl Stangl, Jan Kovac, Molly Schiltgen, Stacia Kraus, Peter de JaegereThe aim of the CoreValve prospective, international, post-Market ADVANCE-II study was to deﬁne the
rate of permanent pacemaker implantation (PPI) after transcatheter aortic valve replacement with
the Medtronic CoreValve System using optimized implantation techniques and application of
international guidelines on cardiac pacing. A total of 194 patients were treated. The PPI rate
for class I/II indications was 18.2%. A lower PPI rate was reached in patients with valves
deployed #6 mm below the aortic annulus than with patients with deeper implants (13.3% vs.
21.1%; p ¼ 0.14). Adherence to clinical best practices leads to a lower rate of new PPI after
transcatheter aortic valve replacement.n EDITORIAL COMMENT
Twofers and Transaortic Valve Replacements 847
David R. Holmes Jr., Michael J. Mack
Percutaneous Mitral Valve Replacement Using a Transvenous, Transseptal Approach:
Transvenous Mitral Valve Replacement850Megan Coylewright, Allison K. Cabalka, Joseph A. Malouf, Jeffrey B. Geske,
Peter M. Pollak, Rakesh M. Suri, Charanjit S. RihalFailure of mitral valve prostheses represents a high-risk clinical scenario for some patients. Transcatheter
options are available and are most often performed via a transapical approach in the operating room.
Four consecutive patients underwent successful transvenous, transseptal mitral valve replacement
with a transcatheter heart valve. All patients were discharged 1 to 2 days after successful valve
replacement with marked improvement in dyspnea. This case series demonstrates the feasibility of
transcatheter mitral valve replacement using only femoral venous access, with a reduction in
complications and length of hospital stay compared with transapical access or redo surgery.PERIPHERAL Hospital Variation in Carotid Stenting Outcomes 858
Beau M. Hawkins, Kevin F. Kennedy, Herbert D. Aronow, Louis L. Nguyen, Christopher J. White,
Kenneth Rosenﬁeld, Sharon-Lise T. Normand, John A. Spertus, Robert W. YehAs carotid artery stenting (CAS) is increasingly being used throughout the United States, assessing
hospital variation in CAS outcomes is critical to understanding and improving the quality of care for
patients with carotid artery disease. Rates of in-hospital stroke or death were examined for 19,381
procedures from 188 hospitals participating in the National Cardiovascular Data Registry–Carotid
Artery Endarterectomy and Revascularization Registry. Unadjusted in-hospital stroke or death rates
ranged from 0 to 18.8%. Risk-standardized rates varied from 1.2% to 4.7%. CAS outcomes varied
4-fold among hospitals, even after adjustment for differences in case mix. Future work is needed to
identify the sources of this variation and develop initiatives to improve patient outcomes.CONTINUED ON PAGE A-29
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INTERVENTIONPhantom Stent Thrombosis: Intracoronary Imaging Insights 864
Fernando Rivero, Javier Cuesta, Amparo Benedicto, Teresa Bastante,
Daniel Rodriguez-Alcudia, M. Cruz Aguilera, Fernando Alfonso
Successful Post-Dilation of a Lotus Transcatheter Aortic Valve in a Case of
Prosthesis Frame Underexpansion Due to Leaﬂet Calciﬁcation866Felipe Fuchs, Vedat Tiyerili, Wilhelm Roell, Eberhard Grube, Nikos Werner,
Georg Nickenig, Jan-Malte Sinning
n ONLINE FEATURE Successful Stenting With Optical Frequency Domain Imaging
Guidance For Spontaneous Coronary Artery Dissectione83Keisuke Satogami, Yasushi Ino, Takashi Kubo, Yasutsugu Shiono, Tsuyoshi Nishiguchi,
Yoshiki Matsuo, Makoto Orii, Takashi Yamano, Tomoyuki Yamaguchi, Kumiko Hirata,
Atsushi Tanaka, Takashi Akasaka
n ONLINE FEATURE Acute Myocardial Infarction Caused by Left Main Coronary Artery
Compression as a Result of a Mycotic Aneurysm of the Sinus of Valsalvae87Kenji Goto, Hideo Takebayashi, Shogo Mukai, Hiroki Yamane, Arata Hagikura,
Yoshimasa Morimoto, Yuetsu Kikuta, Katsumasa Sato, Masahito Taniguchi,
Shigeki Hiramatsu, Seiichi Haruta
n ONLINE FEATURE A 54-Year-Old Woman With a Single Coronary Artery and
Watershed Ischemia Treated With Nitratese91Yonathan F. Melman, Donald E. Cutlip, Saumya Das
n ONLINE FEATURE Cyphering the Mechanism of Late Failure of Bioresorbable
Vascular Scaffolds in Percutaneous Coronary Intervention of the Left Main
Coronary Arterye95Giuseppe Gargiulo, Giovanni Longo, Davide Capodanno, Bruno Francaviglia,
Piera Capranzano, Corrado Tamburino
n ONLINE FEATURE Sinus of Valsalva Aneurysm Causing Extrinsic Compression of the
Left Main Coronary Arterye99Vishal J. Dahya, Prasad Chalasani
n ONLINE FEATURE 1-Year Follow-Up Optical Coherence Tomography of a “Hybrid”
Neocarina After T-Stenting With Small Protrusion Technique Using a Bioresorbable
Vascular Scaffold and a Metallic Stente101Toru Naganuma, Vasileios F. Panoulas, Azeem Latib, Hiroyoshi Kawamoto,
Katsumasa Sato, Tadashi Miyazaki, Antonio Colombo
n ONLINE FEATURE First-in-Human Implantation of a Direct Flow Medical Valve in a
Radiolucent Mitral Annuloplasty Ringe105Azeem Latib, Matteo Montorfano, Eustachio Agricola, Alessandro Castiglioni,
Andrea Blasio, Fabrizio Monaco, Pietro Spagnolo, Ottavio Alﬁeri, Antonio Colombo
n ONLINE FEATURE THESE ARTICLES DO NOT APPEAR IN THE PRINTED ISSUE.
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Asha M. Mahajan, Kaitlyn Dugan, Harmony R. Reynolds
Reply
Giulio Guagliumi, Davide Capodanno, Francesco Saia, for the OCTAVIA Trial
Investigators
Left Atrial Decompression Using Unidirectional Left-to-Right Interatrial Shunt:
Initial Experience in Treating Symptomatic Heart Failure With Preserved Ejection
Fraction With the W-Wave Device870Ignacio J. Amat-Santos, María Del Trigo, Sebastien Bergeron, Philippe Pibarot,
Omar Altisent, Francisco Campelo-Parada, Rishi Puri, Stefan Verheye, Gad Keren,
Rotem Katzenellenbogen, Erez Rozenfeld, William T. Abraham, Mathieu Bernier,
Josep Rodés-CabauEDITOR’S PAGE Should All Stent Patients Have Prolonged Dual Antiplatelet Therapy? 873
Ajay J. Kirtane, Spencer B. King IIICORRECTION 876
